Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 10 mechanisms across 52 industry trials with a known mechanism of action.

See full pipeline →

Adenosine Receptor Agonist

7 trials 1 active 4 sponsors

P2Y12 Platelet Inhibitor

15 trials 4 sponsors

P2Y12

10 trials 3 sponsors

Factor Xa Inhibitor

4 trials 3 sponsors

Nonsteroidal Anti-inflammatory Drug

4 trials 1 sponsor

Anti-anginal

4 trials 1 sponsor

PCSK9 Inhibitor

3 trials 2 sponsors

Anti-coagulant

2 trials 2 sponsors

Contrast Agent for Ultrasound Imaging

2 trials 1 sponsor

Xanthine Oxidase Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

269 industry-sponsored trials across 109 sponsors

View full landscape →

Showing 59 of 59 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
CoreAalst BV	—	—	RECRUITING	2026-06-30	NCT05437900
SPH Qingdao Growful Pharmacetical Co.,Ltd	Yangxinshi tablet	—	RECRUITING	2030-08-31	NCT07110415
Novartis	inclisiran sodium injection	—	ACTIVE NOT RECRUITING	2026-01-30	NCT06941792
Yuhan Corporation	Sarpogrelate Sustained Release/Aspirin	—	COMPLETED	2024-02-28	NCT05730621
Frisch Medical Device Private Limited	—	—	COMPLETED	2024-01-22	NCT07326735
Shanghai Hutchison Pharmaceuticals Limited	—	—	COMPLETED	2023-07-04	NCT04897126
Elixir Medical Corporation	—	—	COMPLETED	2022-12-31	NCT04483791
Biotronik AG	—	—	COMPLETED	2022-09-20	NCT04137510
Tanabe Pharma GmbH	Argatroban	Anti-coagulant [EPC]	COMPLETED	2021-05-06	NCT05740371
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company	Prasugrel	P2Y12	COMPLETED	2020-08-19	NCT03672097
Yuhan Corporation	high-dose rosuvastatin	—	COMPLETED	2019-07-23	NCT04056169
Boston Scientific Corporation	3 months of dual antiplatelet therapy (DAPT)	—	COMPLETED	2019-07-17	NCT02605447
Bristol-Myers Squibb	Apixaban	Factor Xa Inhibitor [EPC]	COMPLETED	2018-11-10	NCT02415400
Sanofi	Alirocumab SAR236553	—	COMPLETED	2018-07-27	NCT02984982
AstraZeneca	—	—	COMPLETED	2017-10-23	NCT02406677
Scitech Produtos Medicos SA	—	—	COMPLETED	2017-09	NCT02504307
Kobe University	EPA and high dose rosuvastatin	—	COMPLETED	2017-06-02	NCT03192579
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2015-09-30	NCT01870921
Sino Medical Sciences Technology Inc.	—	—	COMPLETED	2015-09	NCT02017275
Takeda	Febuxostat	Xanthine Oxidase Inhibitor [EPC]	COMPLETED	2015-03	NCT01763996
Abbott Medical Devices	clopidogrel + aspirin OR prasugrel + aspirin	—	COMPLETED	2015-02	NCT01106534
AstraZeneca	Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)	—	COMPLETED	2014-11	NCT02064985
Scitech Produtos Medicos SA	—	—	COMPLETED	2014-09	NCT01856088
Boston Scientific Corporation	Aspirin	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2014-08	NCT01589978
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2014-06	NCT01603082
Medtronic Vascular	Thienopyridine Therapy	—	COMPLETED	2014-04	NCT01069003
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2014-03	NCT01864005
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2013-09	NCT01523392
HK inno.N Corporation	Closone	—	COMPLETED	2013-08	NCT01765452
Les Laboratoires des Médicaments Stériles	ENOXA®	—	COMPLETED	2013-05	NCT01687491
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2013-05	NCT01523366
Medtronic Vascular	—	—	COMPLETED	2013-03	NCT00846846
Daiichi Sankyo	Prasugrel Loading Dose	—	COMPLETED	2013-02	NCT01587651
Abbott Medical Devices	—	—	COMPLETED	2012-10	NCT01178268
Gilead	Ranolazine	Anti-anginal [EPC]	COMPLETED	2012-10	NCT01425359
Guerbet	iobitridol	—	COMPLETED	2012-09	NCT01255722
Scitech Produtos Medicos SA	—	—	COMPLETED	2012-09	NCT01090609
Sahajanand Medical Technologies Limited	—	—	COMPLETED	2011-12	NCT01368627
Daiichi Sankyo	Prasugrel	P2Y12	COMPLETED	2011-09	NCT01260584
Infraredx	—	—	COMPLETED	2011-08	NCT00905671
Abbott Medical Devices	—	—	COMPLETED	2011-02	NCT01182428
Daiichi Sankyo	Prasugrel	P2Y12	COMPLETED	2010-05	NCT01014624
GSK	fondaparinux background and standard dose UFH	—	COMPLETED	2010-05	NCT00790907
Medtronic Vascular	—	—	COMPLETED	2010-05	NCT00617084
Sanofi	RAMIPRIL HOE498	—	COMPLETED	2010-04-23	NCT03099213
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Atorvastatin	—	COMPLETED	2010-04	NCT00728988
Astellas Pharma Inc	Regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2009-12	NCT00863707
Astellas Pharma Inc	Regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2009-10	NCT00862641
Forest Laboratories	Nebivolol	—	COMPLETED	2009-09	NCT00673075
Hanmi Pharmaceutical Company Limited	Clopidogrel	—	COMPLETED	2009-08	NCT01830491
Innogene Kalbiotech Pte. Ltd	Hypertonic sodium lactate	—	COMPLETED	2009-03	NCT01654653
Merck KGaA, Darmstadt, Germany	Nicorandil	—	TERMINATED	2019-07-09	NCT03010423
AstraZeneca	ticagrelor	P2Y12 Platelet Inhibitor [EPC]	TERMINATED	2015-04	NCT02052635
Sahajanand Medical Technologies Limited	—	—	TERMINATED	2011-03	NCT00936780
Sahajanand Medical Technologies Limited	—	—	TERMINATED	2010-05	NCT00917163
Gilead	Ranolazine	Anti-anginal [EPC]	TERMINATED	2009-06	NCT00832572
ECRI bv	Evolocumab	PCSK9 Inhibitor [EPC]	WITHDRAWN	2021-08-27	NCT03851263
ECRI bv	—	—	WITHDRAWN	2020-03-30	NCT03851276
Gilead	Ranolazine	Anti-anginal [EPC]	WITHDRAWN	2012-10	NCT01334203

Showing 82 of 82 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Jiangsu vcare pharmaceutical technology co., LTD	Vicagrel	—	RECRUITING	2026-12-30	NCT06577519
Novartis	Inclisiran	—	RECRUITING	2027-02-11	NCT07102628
Sinotau Pharmaceutical Group	XTR004	—	RECRUITING	2027-06	NCT07439133
DalCor Pharmaceuticals	Dalcetrapib	—	RECRUITING	2027-08	NCT05918861
ECRI bv	Ziltivekimab	—	RECRUITING	2028-09-01	NCT07276282
MedTrace Pharma A/S	[O-15]-Water PET Myocardial Perfusion Imaging (MPI)	—	RECRUITING	2026-04-30	NCT05134012
Novartis	Inclisiran sodium 300 mg	—	ACTIVE NOT RECRUITING	2026-10-26	NCT05360446
iVascular S.L.U.	1-month DAPT	—	ACTIVE NOT RECRUITING	2027-01-13	NCT05952206
NewAmsterdam Pharma	obicetrapib 10 mg + ezetimibe 10 mg FDC daily	—	ACTIVE NOT RECRUITING	2027-11	NCT06305559
EBI Anti Sepsis BV	EA-230 90mg/kg/hour	—	NOT YET RECRUITING	2027-03-24	NCT07357675
Johnson & Johnson	Milvexian	—	COMPLETED	2026-02-06	NCT05754957
Amgen	Evolocumab	PCSK9 Inhibitor [EPC]	COMPLETED	2025-07-25	NCT03872401
Novartis	Inclisiran	—	COMPLETED	2024-08-07	NCT04873934
CSL Behring	Apolipoprotein A-I [human] (apoA-I)	—	COMPLETED	2023-02-16	NCT03473223
GE Healthcare	PET MPI	—	COMPLETED	2022-05-05	NCT03354273
DalCor Pharmaceuticals	dalcetrapib	—	COMPLETED	2021-10	NCT02525939
Amgen	Evolocumab	PCSK9 Inhibitor [EPC]	COMPLETED	2020-12-18	NCT03570697
Resverlogix Corp	Apabetalone	—	COMPLETED	2020-11-30	NCT02586155
Boston Scientific Corporation	—	—	COMPLETED	2020-01-16	NCT03350542
Scitech Produtos Medicos SA	—	—	COMPLETED	2019-07-30	NCT02400632
Dr. F. Köhler Chemie GmbH	Custodiol-N	—	COMPLETED	2018-11-16	NCT02098772
Johnson & Johnson	Rivaroxaban	Factor Xa Inhibitor [EPC]	COMPLETED	2018-04-19	NCT01877915
Bracco Diagnostics, Inc	Lumason	Contrast Agent for Ultrasound Imaging [EPC]	COMPLETED	2017-11-07	NCT02522481
Sujata Vaidya	SUVED	—	COMPLETED	2017-08	NCT02920125
Bracco Diagnostics, Inc	Lumason	Contrast Agent for Ultrasound Imaging [EPC]	COMPLETED	2017-06-22	NCT02552238
Sino Medical Sciences Technology Inc.	—	—	COMPLETED	2016-11	NCT02236975
Bayer	Gadobutrol (Gadavist, Gadovist, BAY86-4875)	—	COMPLETED	2016-08-06	NCT01890434
GSK	Losmapimod 7.5 mg twice daily	—	COMPLETED	2015-12-14	NCT02145468
ECRI bv	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2015-11-09	NCT01813435
Lisata Therapeutics, Inc.	Auto-CD34+ cells	—	COMPLETED	2015-11	NCT01508910
Medtronic Vascular	—	—	COMPLETED	2015-08	NCT02452736
Scitech Produtos Medicos SA	—	—	COMPLETED	2015-07	NCT01093391
Bayer	Gadobutrol (Gadovist, Gadavist, BAY86-4875)	—	COMPLETED	2015-04-10	NCT01890421
Sanofi	Lixisenatide (AVE0010)	—	COMPLETED	2015-02	NCT01147250
Gilead	Ranolazine	Anti-anginal [EPC]	COMPLETED	2015-02	NCT01442038
Astellas Pharma Global Development, Inc.	Regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2014-12	NCT01618669
Boston Scientific Corporation	—	—	COMPLETED	2014-09	NCT01665053
Abbott Diagnostics Division	—	—	COMPLETED	2014-08	NCT01608100
Angel Medical Systems	—	—	COMPLETED	2014-05-01	NCT00781118
GSK	Darapladib 160 mg	—	COMPLETED	2014-04-01	NCT01000727
Air Liquide Santé International	Xenon	—	COMPLETED	2014-04	NCT01294163
Bayer	D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV	—	COMPLETED	2014-04	NCT00910065
Advanced Accelerator Applications	Rubidium-82	—	COMPLETED	2013-11	NCT01379677
The Medicines Company	Bivalirudin	Anti-coagulant [EPC]	COMPLETED	2013-08	NCT01087723
Lantheus Medical Imaging	Flurpiridaz F18	—	COMPLETED	2013-07	NCT01347710
Sanofi	Otamixaban	—	COMPLETED	2013-05	NCT01076764
Takeda	Alogliptin	—	COMPLETED	2013-04	NCT00968708
Novartis	Aliskiren	—	COMPLETED	2013-01	NCT00853827
Eli Lilly	Prasugrel	P2Y12	COMPLETED	2013-01	NCT01015287
The Medicines Company	cangrelor P2Y12 (platelet) inhibitor	—	COMPLETED	2012-12	NCT01156571
Boston Scientific Corporation	—	—	COMPLETED	2012-12	NCT01635881
Roche	Dalcetrapib (RO4607381)	—	COMPLETED	2012-09	NCT00658515
AbbVie (prior sponsor, Abbott)	ABT-335	—	COMPLETED	2012-09	NCT00616772
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2012-07	NCT01294462
Eli Lilly	Clopidogrel	—	COMPLETED	2012-04	NCT00699998
Roche	dalcetrapib	—	COMPLETED	2012-03	NCT01323153
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Rivaroxaban 2.5 mg	—	COMPLETED	2011-09	NCT00809965
Boston Scientific Corporation	Aspirin	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2011-03	NCT01500434
Boston Scientific Corporation	—	—	COMPLETED	2011-03	NCT01080261
Abbott Medical Devices	—	—	COMPLETED	2011-03	NCT00916370
Omicron Pharmaceuticals	—	—	COMPLETED	2011-03	NCT01272986
Boston Scientific Corporation	Aspirin	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2010-09	NCT00823212
Astellas Pharma Inc	regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2010-07-15	NCT00826280
Eli Lilly	Prasugrel	P2Y12	COMPLETED	2010-06	NCT00830960
Kastle Therapeutics, LLC	Mipomersen sodium	—	COMPLETED	2010-05	NCT00770146
Kastle Therapeutics, LLC	Mipomersen	—	COMPLETED	2010-05	NCT00794664
Boston Scientific Corporation	Aspirin	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2010-02	NCT01510327
Ono Pharmaceutical Co., Ltd.	ONO-1101	—	COMPLETED	2010-02	NCT00924586
Kastle Therapeutics, LLC	mipomersen sodium	—	COMPLETED	2009-12	NCT00706849
Boston Scientific Corporation	—	—	COMPLETED	2009-09	NCT00824434
Merck	anacetrapib	—	COMPLETED	2009-07-02	NCT00685776
Cordis US Corp.	—	—	COMPLETED	2008-12	NCT00722579
Abbott	ABT-335	—	COMPLETED	2008-10	NCT00639158
Miltenyi Biotec B.V. & Co. KG	CD133+ autologous bone marrow stem cell	—	TERMINATED	2016-03	NCT00950274
Regado Biosciences, Inc.	pegnivacogin/anivamersen	—	TERMINATED	2014-08	NCT01848106
Forest Laboratories	Apadenoson SPECT-MPI	—	TERMINATED	2012-04	NCT01313572
Forest Laboratories	Apadenoson SPECT-MPI	—	TERMINATED	2012-04	NCT00990327
Anthera Pharmaceuticals	A-002, varespladib methyl	—	TERMINATED	2012-03	NCT01130246
Cordis US Corp.	—	—	TERMINATED	2011-11	NCT01202058
Bristol-Myers Squibb	Apixaban	Factor Xa Inhibitor [EPC]	TERMINATED	2011-03	NCT00831441
Lantheus Medical Imaging	Flurpiridaz F18	—	WITHDRAWN	2014-02	NCT01681524
AstraZeneca	90 mg Ticagrelor	—	WITHDRAWN	2013-04	NCT01757262

Showing 81 of 81 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Beijing Inno Medicine Co., Ltd.	Dose 1 YN001	—	RECRUITING	2026-06	NCT06700720
Research Institute of Geroprotective Technologies	Aroxxen	—	RECRUITING	2026-10-01	NCT07397351
GE Healthcare	Regadenoson	Adenosine Receptor Agonist [EPC]	RECRUITING	2026-12	NCT04604782
XyloCor Therapeutics, Inc.	—	—	RECRUITING	2026-12-31	NCT07048808
Abcentra	Orticumab	—	RECRUITING	2027-02-08	NCT06927739
Sirius Therapeutics Co., Ltd.	SRSD107	—	RECRUITING	2027-12	NCT07318155
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT1002 Injection	—	RECRUITING	2024-12	NCT06533358
Ribocure Pharmaceuticals AB	RBD4059	—	ACTIVE NOT RECRUITING	2026-04-28	NCT06717074
Elixir Medical Corporation	—	—	ACTIVE NOT RECRUITING	2022-12-02	NCT05033964
XyloCor Therapeutics, Inc.	XC001	—	NOT YET RECRUITING	2026-12-30	NCT07118449
Beijing Inno Medicine Co., Ltd.	YN001/Placebo 40mg	—	NOT YET RECRUITING	2027-07-31	NCT07521007
Hexun Biosciences Co., LTD.	HeXell-2020	—	NOT YET RECRUITING	2027-12-31	NCT07137104
Cell>Point LLC	—	—	NOT YET RECRUITING	2025-12	NCT01899833
Novartis	DFV890	—	COMPLETED	2024-12-17	NCT06031844
Novartis	MAS825	—	COMPLETED	2024-10-27	NCT06097663
AstraZeneca	MEDI6570	—	COMPLETED	2023-11-08	NCT04610892
Imbria Pharmaceuticals, Inc.	IMB-1018972	—	COMPLETED	2023-09-21	NCT04826172
Sinotau Pharmaceutical Group	XTR004	—	COMPLETED	2023-05-09	NCT05885841
XyloCor Therapeutics, Inc.	AdVEGFXC1	—	COMPLETED	2023-01-31	NCT04125732
Bristol-Myers Squibb	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2022-11-14	NCT05093790
Abcentra	Orticumab	—	COMPLETED	2022-11-11	NCT04776629
GE Healthcare	Flurpiridaz (18F) Injection	—	COMPLETED	2022-05-26	NCT04594941
AstraZeneca	AZD5718	—	COMPLETED	2020-04-08	NCT03317002
Jiangsu vcare pharmaceutical technology co., LTD	Vicagrel 5mg	—	COMPLETED	2019-06-11	NCT03599284
Medicure	Short Tirofiban	—	COMPLETED	2018-12	NCT01522417
MedImmune LLC	MEDI5884	—	COMPLETED	2018-11-09	NCT03351738
Viatris Innovation GmbH	Selatogrel	—	COMPLETED	2018-08-18	NCT03384966
Cerenis Therapeutics, SA	CER-001	—	COMPLETED	2016-11	NCT02484378
The Medicines Company	MDCO-216	—	COMPLETED	2016-10-26	NCT02678923
Johnson & Johnson	Acetylsalicylic acid	—	COMPLETED	2016-10-14	NCT02293395
MedImmune LLC	MEDI6012	—	COMPLETED	2016-08-20	NCT02601560
Novartis	Serelaxin	—	COMPLETED	2016-08-17	NCT01979614
Fluoropharma, Inc.	CardioPET™	—	COMPLETED	2016-07	NCT01826773
The Medicines Company	Cangrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2014-01-20	NCT01979445
The Medicines Company	Cangrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2013-07	NCT01852019
Roche	RO4905417	—	COMPLETED	2013-05	NCT01245634
Roche	MPSK3169A	—	COMPLETED	2013-05	NCT01609140
Resverlogix Corp	RVX000222	—	COMPLETED	2013-05	NCT01067820
The Medicines Company	cangrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2013-02	NCT01766466
Cell>Point LLC	—	—	COMPLETED	2013-02	NCT01778218
Bayer	UFH	—	COMPLETED	2013-01-29	NCT01442792
Cerenis Therapeutics, SA	CER-001	—	COMPLETED	2012-10	NCT01201837
Micell Technologies	—	—	COMPLETED	2012-09	NCT01247428
OrbusNeich	—	—	COMPLETED	2012-08	NCT01405287
Astellas Pharma Inc	regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2012-07-02	NCT01334918
Micell Technologies	—	—	COMPLETED	2012-06	NCT01294748
Resverlogix Corp	RVX000222	—	COMPLETED	2012-06	NCT01423188
Dr. F. Köhler Chemie GmbH	Custodiol-N	—	COMPLETED	2012-05	NCT01444235
GSK	GW856553	—	COMPLETED	2012-03-06	NCT00910962
Corindus Inc.	—	—	COMPLETED	2011-12	NCT01275092
Eli Lilly	Prasugrel	P2Y12	COMPLETED	2011-11	NCT01115738
Terumo Europe N.V.	—	—	COMPLETED	2011-09	NCT01271361
The Medicines Company	cangrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2011-06	NCT00767507
AstraZeneca	ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2011-03	NCT01118325
Stereotaxis	—	—	COMPLETED	2011-03	NCT01131793
Ischemix, LLC	CMX-2043	—	COMPLETED	2011-03	NCT00984802
Astellas Pharma Europe B.V.	YM150	—	COMPLETED	2011-02	NCT00994292
Regado Biosciences, Inc.	REG1	—	COMPLETED	2011-01	NCT00932100
Roche	Dalcetrapib (RO4607381)	—	COMPLETED	2010-11	NCT00655473
Molecular Targeting Technologies, Inc.	99mTc-glucarate solution	—	COMPLETED	2010-09	NCT00614354
Resverlogix Corp	RVX000222	—	COMPLETED	2010-06	NCT01058018
Takeda	TAK-442	—	COMPLETED	2010-06	NCT00677053
Roche	dalcetrapib	—	COMPLETED	2010-05	NCT00655538
Corindus Inc.	—	—	COMPLETED	2010-05	NCT01076036
Biotronik AG	—	—	COMPLETED	2010-04	NCT01214148
Anthera Pharmaceuticals	Varespladib Methyl (A-002)	—	COMPLETED	2010-01	NCT00743925
Resverlogix Corp	RVX000222	—	COMPLETED	2009-08	NCT00768274
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2009-03	NCT00642811
Eli Lilly	prasugrel	P2Y12	COMPLETED	2009-01	NCT00642174
Sinotau Pharmaceutical Group	XTR004	—	TERMINATED	2025-03-05	NCT07187895
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT1002 for Injection	—	TERMINATED	2023-08-31	NCT04723186
Lisata Therapeutics, Inc.	CLBS16	—	TERMINATED	2022-09-28	NCT04614467
Sanofi	SAR407899	—	TERMINATED	2018-07-23	NCT03236311
Novartis	pradigastat (LCQ908)	—	TERMINATED	2014-06	NCT01474434
Resverlogix Corp	RVX000222	—	TERMINATED	2013-06	NCT01863225
PolyMedix, Inc.	PMX-60056	—	TERMINATED	2012-06	NCT01312935
Eli Lilly	Prasugrel	P2Y12	TERMINATED	2011-04	NCT00910299
Pfizer	Apixaban	Factor Xa Inhibitor [EPC]	TERMINATED	2010-12	NCT00852397
Gilead	regadenoson	Adenosine Receptor Agonist [EPC]	TERMINATED	2010-04	NCT00907764
TCA Cellular Therapy	MESENDO	—	SUSPENDED	2014-05	NCT00790764
Bayer	Riociguat (BAY63-2521)	—	WITHDRAWN	2013-01	NCT01165931

Showing 47 of 47 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Verve Therapeutics, Inc.	VERVE-102	—	RECRUITING	2026-08	NCT06164730
Roche	RO7763505	—	RECRUITING	2028-02-15	NCT07495813
Bayer	Nitroglycerin spray	—	NOT YET RECRUITING	2027-05-07	NCT07431294
Honya Medical Inc	MCRcI® stem cells	—	NOT YET RECRUITING	2026-01-01	NCT04052191
Jiangsu vcare pharmaceutical technology co., LTD	Vicagrel Capsules	—	COMPLETED	2025-08-22	NCT07067775
Indication Bioscience LLC	Atorvo+™ (Arm1)	—	COMPLETED	2025-05-14	NCT06615284
Brillian Pharma Inc.	Amlodipine Freeze-Dried Powder for Oral Solution 5 mg	—	COMPLETED	2023-04-17	NCT05808725
Jiangsu vcare pharmaceutical technology co., LTD	vicagrel Capsules	—	COMPLETED	2022-11-03	NCT05162053
Jiangsu vcare pharmaceutical technology co., LTD	vicagrel	—	COMPLETED	2021-10-20	NCT04919551
Sinotau Pharmaceutical Group	XTR003	—	COMPLETED	2021-08-27	NCT05136391
Sinotau Pharmaceutical Group	—	—	COMPLETED	2021-07-30	NCT05195879
AstraZeneca	AZD5718 tablet, Formulation A	—	COMPLETED	2020-03-09	NCT04210388
Shin Poong Pharmaceutical Co. Ltd.	SP-8008 Prototype Capsule A	—	COMPLETED	2020-01-23	NCT04770194
AstraZeneca	Treatment A	—	COMPLETED	2019-10-31	NCT04087187
Sanofi	SAR247799	—	COMPLETED	2018-12-22	NCT03462017
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2018-11-29	NCT03504982
AstraZeneca	AZD5718 oral suspension	—	COMPLETED	2018-06-12	NCT03400488
Chong Kun Dang Pharmaceutical	D578	—	COMPLETED	2018-06-04	NCT03671941
AstraZeneca	Form 1 of AZD5718 tablets	—	COMPLETED	2018-04-18	NCT03420092
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2018-02-07	NCT03255512
AstraZeneca	AZD5718 IR tablet	—	COMPLETED	2017-03-01	NCT02963116
Synektik S.A.	—	—	COMPLETED	2017-02	NCT02720354
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2016-05-18	NCT02617550
Bristol-Myers Squibb	BMS-919373	—	COMPLETED	2014-05	NCT02089061
GSK	Losmapimod	—	COMPLETED	2013-04-23	NCT01756495
LG Life Sciences	LC23-1306	—	COMPLETED	2012-11	NCT01526577
GSK	Losmapimod for single dose	—	COMPLETED	2012-10-26	NCT01648192
MedImmune LLC	ACP-501	—	COMPLETED	2012-09	NCT01554800
Yuhan Corporation	YH14659	—	COMPLETED	2012-04	NCT01657071
Fluoropharma, Inc.	BFPET	—	COMPLETED	2012-01	NCT00733460
Yuhan Corporation	YH14659	—	COMPLETED	2011-11	NCT01422109
Eli Lilly	prasugrel	P2Y12	COMPLETED	2011-10	NCT01107912
Chong Kun Dang Pharmaceutical	Clopidogrel and Aspirin	—	COMPLETED	2011-09	NCT01496261
Eli Lilly	prasugrel	P2Y12	COMPLETED	2011-08	NCT01107925
Lee's Pharmaceutical Limited	Anfibatide	—	COMPLETED	2011-03	NCT01588132
Chong Kun Dang Pharmaceutical	Clopidogrel	—	COMPLETED	2011-01	NCT01663038
Merck	Pantoprazole	—	COMPLETED	2010-12	NCT01358344
Novartis	APL180	—	COMPLETED	2009-10	NCT00907998
Lantheus Medical Imaging	[3H] BMS747158	—	COMPLETED	2009-07	NCT00930631
Merck	telcagepant	—	COMPLETED	2009-02-28	NCT01294709
TCA Cellular Therapy	MESENDO	—	COMPLETED	2008-12	NCT00643981
AstraZeneca	AZD6140	—	COMPLETED	2008-07	NCT00738842
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT1002 for Injection	—	TERMINATED	2022-06-29	NCT05323136
IlDong Pharmaceutical Co Ltd	APD791	—	TERMINATED	2016-04	NCT02419820
IlDong Pharmaceutical Co Ltd	Clopidogrel	—	TERMINATED	2014-03	NCT02034292
Miltenyi Biotec, Inc.	—	—	TERMINATED	2013-10	NCT01721902
Eli Lilly	clopidogrel	—	TERMINATED	2010-12	NCT01107899

Novel Drugs by Company (New molecular entities)

BRACCO 1 drug

CARDIOGEN-82

RUBIDIUM CHLORIDE RB-82

NDA 1989

MEDI-PHYSICS 1 drug

MYOVIEW

TECHNETIUM TC-99M TETROFOSMIN KIT

GE HLTHCARE 1 drug

Reformulations (14 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.